China Universal Asset Management Co. Ltd. Raises Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

China Universal Asset Management Co. Ltd. grew its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 10.5% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 21,468 shares of the company’s stock after buying an additional 2,047 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Neurocrine Biosciences were worth $2,930,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in NBIX. State Street Corp increased its holdings in shares of Neurocrine Biosciences by 11.7% in the third quarter. State Street Corp now owns 5,148,293 shares of the company’s stock valued at $593,186,000 after purchasing an additional 539,936 shares during the period. Los Angeles Capital Management LLC increased its stake in Neurocrine Biosciences by 639.6% in the 3rd quarter. Los Angeles Capital Management LLC now owns 420,748 shares of the company’s stock valued at $48,479,000 after buying an additional 363,863 shares during the period. Braidwell LP increased its stake in Neurocrine Biosciences by 20.9% in the 3rd quarter. Braidwell LP now owns 917,674 shares of the company’s stock valued at $105,734,000 after buying an additional 158,665 shares during the period. BNP Paribas Financial Markets raised its position in Neurocrine Biosciences by 23.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 533,324 shares of the company’s stock worth $61,450,000 after buying an additional 102,715 shares during the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec lifted its stake in shares of Neurocrine Biosciences by 12.3% in the 3rd quarter. Caisse DE Depot ET Placement DU Quebec now owns 736,910 shares of the company’s stock worth $84,907,000 after acquiring an additional 80,792 shares during the period. Institutional investors and hedge funds own 92.59% of the company’s stock.

Neurocrine Biosciences Price Performance

NASDAQ:NBIX opened at $151.82 on Friday. The firm has a market cap of $15.37 billion, a PE ratio of 40.70 and a beta of 0.33. The firm has a 50 day simple moving average of $136.97 and a 200-day simple moving average of $131.62. Neurocrine Biosciences, Inc. has a 1-year low of $110.95 and a 1-year high of $157.98.

Insider Buying and Selling at Neurocrine Biosciences

In other news, insider Jude Onyia sold 2,331 shares of the stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $126.29, for a total transaction of $294,381.99. Following the transaction, the insider now directly owns 15,449 shares in the company, valued at $1,951,054.21. This represents a 13.11 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Kyle Gano sold 65,000 shares of the company’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $141.50, for a total value of $9,197,500.00. Following the sale, the chief executive officer now owns 135,392 shares of the company’s stock, valued at approximately $19,157,968. The trade was a 32.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 214,799 shares of company stock worth $31,513,583. Insiders own 4.30% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Wedbush reiterated an “outperform” rating and set a $148.00 price target on shares of Neurocrine Biosciences in a research note on Monday, December 16th. UBS Group increased their price target on shares of Neurocrine Biosciences from $162.00 to $176.00 and gave the company a “buy” rating in a report on Thursday. HC Wainwright reissued a “buy” rating and set a $190.00 price objective on shares of Neurocrine Biosciences in a report on Monday, December 16th. BMO Capital Markets dropped their target price on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating for the company in a report on Thursday, October 17th. Finally, Raymond James reiterated an “outperform” rating and set a $155.00 price target on shares of Neurocrine Biosciences in a research report on Thursday, October 10th. Five investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $166.10.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.